$3.71
5.84% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US92337C1045
Symbol
VSTM
Sector
Industry

Verastem, Inc. Stock price

$3.71
-0.86 18.82% 1M
+0.81 27.93% 6M
-4.43 54.42% YTD
-4.59 55.30% 1Y
-23.05 86.14% 3Y
-13.09 77.92% 5Y
-100.09 96.43% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.23 5.84%
ISIN
US92337C1045
Symbol
VSTM
Sector
Industry

Key metrics

Market capitalization $165.12m
Enterprise Value $114.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.43
P/S ratio (TTM) P/S ratio 16.51
P/B ratio (TTM) P/B ratio 13.51
Revenue (TTM) Revenue $10.00m
EBIT (operating result TTM) EBIT $-114.51m
Free Cash Flow (TTM) Free Cash Flow $-109.38m
Cash position $113.42m
EPS (TTM) EPS $-3.19
P/E forward negative
P/S forward 18.45
EV/Sales forward 12.77
Short interest 4.52%
Show more

Is Verastem, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Verastem, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Verastem, Inc. forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Verastem, Inc. forecast:

Buy
100%

Financial data from Verastem, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
10 10
-
100%
- Direct Costs 0.02 0.02
78% 78%
0%
9.98 9.98
11,189% 11,189%
100%
- Selling and Administrative Expenses 41 41
48% 48%
414%
- Research and Development Expense 83 83
67% 67%
830%
-114 -114
47% 47%
-1,145%
- Depreciation and Amortization 0.02 0.02
78% 78%
0%
EBIT (Operating Income) EBIT -115 -115
47% 47%
-1,145%
Net Profit -93 -93
22% 22%
-935%

In millions USD.

Don't miss a Thing! We will send you all news about Verastem, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verastem, Inc. Stock News

Neutral
Business Wire
11 days ago
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced preliminary clinical data for the triplet combination of avutometinib and sotorasib plus defactinib in the RAMP 203 Phase 1/2 study in KRAS G12C mutant advanced non-small cell lung cancer (NSCLC). No dose-limiting toxicities (DLTs)...
Positive
Seeking Alpha
about one month ago
Verastem's avutometinib and defactinib show promising clinical progress for recurrent KRAS-mutant LGSOC, with potential FDA approval and market launch by mid-2025. The company's strong cash position and strategic focus on RAS-driven cancers offer significant growth opportunities without imminent dilution risks. Upcoming catalysts include FDA filing decisions, interim data from NSCLC and pancrea...
Neutral
Business Wire
about one month ago
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3rd at 11:15 am EST. A live webcast of the fireside chat can be accessed under “Events & Present...
More Verastem, Inc. News

Company Profile

Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Head office United States
CEO Dan Paterson
Employees 73
Founded 2010
Website www.verastem.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today